BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 33087808)

  • 1. Quantitative PCR methodology with a volume-based unit for the sophisticated cellular kinetic evaluation of chimeric antigen receptor T cells.
    Yamamoto S; Matsumoto SI; Goto A; Ugajin M; Nakayama M; Moriya Y; Hirabayashi H
    Sci Rep; 2020 Oct; 10(1):17884. PubMed ID: 33087808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights on Droplet Digital PCR-Based Cellular Kinetics and Biodistribution Assay Support for CAR-T Cell Therapy.
    Sugimoto H; Chen S; Minembe JP; Chouitar J; He X; Wang H; Fang X; Qian MG
    AAPS J; 2021 Mar; 23(2):36. PubMed ID: 33655393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Considerations in the development and validation of real-time quantitative polymerase chain reaction and its application in regulated bioanalysis to characterize the cellular kinetics of CAR-T products in clinical studies.
    Yang TY; Doddareddy R
    Bioanalysis; 2021 Jan; 13(2):115-128. PubMed ID: 33356555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioanalytical Methods for Characterization of CAR-T Cellular Kinetics: Comparison of PCR Assays and Matrices.
    Masilamani M; Jawa V; Dai Y; Das R; Park A; Lamba M; Wu F; Zheng X; Lu E; Gleason C; Mack T; Mora J; Surapaneni S
    Clin Pharmacol Ther; 2023 Sep; 114(3):664-672. PubMed ID: 37422675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.
    Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W
    J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of chimeric antigen receptor surface expression by a small molecule switch.
    Juillerat A; Tkach D; Busser BW; Temburni S; Valton J; Duclert A; Poirot L; Depil S; Duchateau P
    BMC Biotechnol; 2019 Jul; 19(1):44. PubMed ID: 31269942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma.
    Sahin A; Sanchez C; Bullain S; Waterman P; Weissleder R; Carter BS
    PLoS One; 2018; 13(7):e0199414. PubMed ID: 29975720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunobiology of chimeric antigen receptor T cells and novel designs.
    Walsh Z; Yang Y; Kohler ME
    Immunol Rev; 2019 Jul; 290(1):100-113. PubMed ID: 31355496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges of driving CD30-directed CAR-T cells to the clinic.
    Grover NS; Savoldo B
    BMC Cancer; 2019 Mar; 19(1):203. PubMed ID: 30841880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment of a Quantitative Polymerase Chain Reaction Assay for Monitoring Chimeric Antigen Receptor T Cells in Peripheral Blood.
    Wang H; Du X; Chen WH; Lou J; Xiao HL; Pan YM; Chen H; An N; Zhang QX
    Transplant Proc; 2018; 50(1):104-109. PubMed ID: 29407291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity.
    Yu S; Yi M; Qin S; Wu K
    Mol Cancer; 2019 Aug; 18(1):125. PubMed ID: 31429760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
    Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
    Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAR T Cells Generated Using Sleeping Beauty Transposon Vectors and Expanded with an EBV-Transformed Lymphoblastoid Cell Line Display Antitumor Activity In Vitro and In Vivo.
    Chicaybam L; Abdo L; Carneiro M; Peixoto B; Viegas M; de Sousa P; Fornazin MC; Spago MC; Albertoni Laranjeira AB; de Campos-Lima PO; Nowill A; Barros LRC; Bonamino MH
    Hum Gene Ther; 2019 Apr; 30(4):511-522. PubMed ID: 30793967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells.
    Hu B; Zou Y; Zhang L; Tang J; Niedermann G; Firat E; Huang X; Zhu X
    Hum Gene Ther; 2019 Apr; 30(4):446-458. PubMed ID: 29706119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function.
    Salter AI; Ivey RG; Kennedy JJ; Voillet V; Rajan A; Alderman EJ; Voytovich UJ; Lin C; Sommermeyer D; Liu L; Whiteaker JR; Gottardo R; Paulovich AG; Riddell SR
    Sci Signal; 2018 Aug; 11(544):. PubMed ID: 30131370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells.
    Darowski D; Kobold S; Jost C; Klein C
    MAbs; 2019; 11(4):621-631. PubMed ID: 30892136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative analysis and optimization of protocols for producing recombinant lentivirus carrying the anti-Her2 chimeric antigen receptor gene.
    Yuan W; Chen J; Cao Y; Yang L; Shen L; Bian Q; Bin S; Li P; Cao J; Fang H; Gu H; Li H
    J Gene Med; 2018 Jul; 20(7-8):e3027. PubMed ID: 29851200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitive detection of integrated and free transcripts in chimeric antigen receptor T-cell manufactured cell products using droplet digital polymerase chain reaction.
    Wiltshire TD; Milosevic D; Jacob EK; Grebe SK; Dietz AB
    Cytotherapy; 2021 May; 23(5):452-458. PubMed ID: 33715950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.